Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
Clinical Interventions in Aging, 06/04/09
Miller J et al. - Medical treatments of symptomatic BPH include; 1) the 5alpha-reductase inhibitors, 2) the alpha1-adrenergic antagonists, and 3) the combination of a 5alpha-reductase inhibitor and a alpha1-adrenergic antagonist. Selective alpha1-adrenergic antagonists relax the smooth muscle of the prostate and bladder neck without affecting the detrussor muscle of the bladder wall, thus decreasing the resistance to urine flow without compromising bladder contractility. Clinical trials have shown that alpha1-adrenergic antagonists decrease LUTS and increase urinary flow rates in men with symptomatic BPH, but do not reduce the long-term risk of urinary retention or need for surgical intervention. Inhibitors of 5alpha-reductase decrease production of dihydrotestosterone within the prostate resulting in decreased prostate volumes, increased peak urinary flow rates, improvement of symptoms, and decreased risk of acute urinary retention and need for surgical intervention. Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5alpha-reductase inhibitor dutasteride and the alpha1-adrenergic antagonist tamsulosin offer significant improvements from baseline compared with either drug alone.
Related Articles
The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery
BJU International, 11/09/09
Relevance Score: 66%
Radical prostatectomy as initial monotherapy for patients with pathologically confirmed high-grade prostate cancer
BJU International, 11/06/09
Relevance Score: 66%
A pure primary low-grade neuroendocrine carcinoma (carcinoid tumor) of the prostate
International Urology and Nephrology, 11/04/09
Relevance Score: 64%
Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
Indian Journal of Urology, 10/05/09
Relevance Score: 63%
Zinc and prostatic cancer
Current Opinion in Clinical Nutrition & Metabolic Care, 10/16/09
Relevance Score: 48%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/17/09
Is antibiotic prophylaxis effective in preventing urinary tract infections in patients with vesicoureteral reflux
Expert Review of Anti-infective Therapy, 12/17/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer
Clinical Cancer Research, 12/17/09
Men Presenting for Radical Prostatectomy on Preoperative Statin Therapy Have Reduced Serum Prostate Specific Antigen
The Journal of Urology, 12/17/09
Robotic Assisted Laparoscopic Salvage Prostatectomy for Radiation Resistant Prostate Cancer
The Journal of Urology, 12/17/09
Article Search
Sponsor


See Latest Articles


